title: High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up.
abstract: Twenty-one consecutive previously untreated patients with low-grade non-Hodgkin's lymphoma were entered into a trial of mitoxantrone (5 mg/m2 daily for 3 days repeated every 3 weeks) between 1985 and 1986. After 8 to 11 cycles of treatment not exceeding a cumulative dose of 165 mg/m2, the patients were observed without further treatment. Seven patients had small lymphocytic lymphomas, 10 had follicular small cleaved cell lymphomas, and 4 had follicular mixed small- and large-cell lymphomas. As previously reported, both hematologic and nonhematologic toxicity was modest. Nine patients achieved complete remission (CR) and 12 partial remission (PR) (CR plus PR = 100%). In the subsequent 4- to 5-year observation phase, 1 patient withdrew from the study, 10 patients relapsed, and 10 remain in unmaintained remission (7 CR, 3 stable PR). Three relapsed patients have died of treatment-resistant disease. No long-term side effects have been observed. Follow-up studies of left ventricular ejection fraction using multiple-gated acquisition scintigraphy showed no significant decrease in cardiac function.
authors: Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
authors: N I
authors: NI
authors: Nissen
authors: S W
authors: SW
authors: Hansen
mesh_terms: D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D015637:Gated Blood-Pool Imaging; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000009:adverse effects; D009367:Neoplasm Staging; D012074:Remission Induction; D013318:Stroke Volume / Q000187:drug effects; D015996:Survival Rate
chemical_list: D008942:Mitoxantrone